Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10298793 | 0.89 | MAPT (0.45) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL10298786 | 0.88 | HDAC1 (0.54) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL10176981 | 0.81 | JAK2 (0.52) | LMNASMN1; SMN2MAPTALPGHTT | |
| SCHEMBL6247270 | 0.77 | MAPK1 (0.50) | LMNAHDAC1HDAC8TSHRCNR2 | |
| SCHEMBL6244917 | 0.77 | TSHR (0.50) | HDAC1TSHRCNR2MAPK1 | |
| SCHEMBL21307563 | 0.77 | POLB (0.62) | KMT2ASMN1; SMN2MAPTALPGHTT | |
| SCHEMBL10298695 | 0.76 | CNR2 (0.47) | SMN1; SMN2MAPTALPGHTTCNR2 | |
| SCHEMBL8291370 | 0.75 | HDAC1 (0.81) | MEN1KMT2ALMNAHDAC1HDAC8 | |
| SCHEMBL11876883 | 0.74 | MEN1 (0.43) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL10298794 | 0.73 | PPARG (0.50) | LMNAMAPTHDAC1HDAC8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | MEN1 1399/4885KMT2A 512/4885LMNA 4541/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | MEN1 1399/4885KMT2A 512/4885LMNA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.